Page last updated: 2024-11-13
proximicin c
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
proximicin C: antineoplastic agent isolated from Verrucosispora; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 24829332 |
CHEMBL ID | 549354 |
MeSH ID | M0522358 |
Synonyms (3)
Synonym |
---|
CHEMBL549354 |
proximicin c |
methyl n-[5-[[5-[2-(1h-indol-3-yl)ethylcarbamoyl]furan-3-yl]carbamoyl]furan-3-yl]carbamate |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (24)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1657466 | Antibacterial activity against Micrococcus luteus SCSIO ML01 by CLSI based susceptibility test method | 2020 | Journal of natural products, 04-24, Volume: 83, Issue:4 | Proximicins F and G and Diproximicin A: Aminofurans from the Marine-Derived |
AID649519 | Antimicrobial activity against Escherichia coli NCTC 10418 after 24 hrs by MTT assay | 2012 | Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6 | Efficient synthesis and biological evaluation of proximicins A, B and C. |
AID649514 | Antimicrobial activity against Staphylococcus aureus ATCC 29523 after 24 hrs by MTT assay | 2012 | Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6 | Efficient synthesis and biological evaluation of proximicins A, B and C. |
AID1657467 | Inhibition of alpha-glucosidase (unknown origin) at 20 uM using pNPG as substrate preincubated for 15 mins followed by substrate addition and measured after 15 mins | 2020 | Journal of natural products, 04-24, Volume: 83, Issue:4 | Proximicins F and G and Diproximicin A: Aminofurans from the Marine-Derived |
AID1657468 | Inhibition of tyrosinase (unknown origin) at 20 uM using L-DOPA as substrate | 2020 | Journal of natural products, 04-24, Volume: 83, Issue:4 | Proximicins F and G and Diproximicin A: Aminofurans from the Marine-Derived |
AID649513 | Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay | 2012 | Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6 | Efficient synthesis and biological evaluation of proximicins A, B and C. |
AID425453 | Cytotoxicity against human AGS cells after 48 hrs by sulforhodamine B assay | 2009 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 19, Issue:14 | Synthesis and evaluation of a netropsin-proximicin-hybrid library for DNA binding and cytotoxicity. |
AID649512 | Cytotoxicity against human U87MG cells after 48 hrs by MTT assay | 2012 | Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6 | Efficient synthesis and biological evaluation of proximicins A, B and C. |
AID649510 | Induction of apoptosis in human Jurkat 16 cells assessed as DNA fragments release from apoptotic nuclei at 50 ug/ml after 48 hrs by propidium iodide based flow cytometry analysis | 2012 | Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6 | Efficient synthesis and biological evaluation of proximicins A, B and C. |
AID649515 | Antimicrobial activity against epidemic methicillin-resistant Staphylococcus aureus 16 after 24 hrs by MTT assay | 2012 | Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6 | Efficient synthesis and biological evaluation of proximicins A, B and C. |
AID1657464 | Antibacterial activity against methicillin-resistant Staphylococcus aureus shhsA1 by CLSI based susceptibility test method | 2020 | Journal of natural products, 04-24, Volume: 83, Issue:4 | Proximicins F and G and Diproximicin A: Aminofurans from the Marine-Derived |
AID1657471 | Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by SRB assay | 2020 | Journal of natural products, 04-24, Volume: 83, Issue:4 | Proximicins F and G and Diproximicin A: Aminofurans from the Marine-Derived |
AID1657470 | Cytotoxicity against human SF268 cells assessed as reduction in cell viability after 48 hrs by SRB assay | 2020 | Journal of natural products, 04-24, Volume: 83, Issue:4 | Proximicins F and G and Diproximicin A: Aminofurans from the Marine-Derived |
AID1657465 | Antibacterial activity against Bacillus subtilis 1064 by CLSI based susceptibility test method | 2020 | Journal of natural products, 04-24, Volume: 83, Issue:4 | Proximicins F and G and Diproximicin A: Aminofurans from the Marine-Derived |
AID649517 | Antimicrobial activity against epidemic methicillin-resistant Staphylococcus aureus 15 after 24 hrs by MTT assay | 2012 | Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6 | Efficient synthesis and biological evaluation of proximicins A, B and C. |
AID425455 | Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay | 2009 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 19, Issue:14 | Synthesis and evaluation of a netropsin-proximicin-hybrid library for DNA binding and cytotoxicity. |
AID1657473 | Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by SRB assay | 2020 | Journal of natural products, 04-24, Volume: 83, Issue:4 | Proximicins F and G and Diproximicin A: Aminofurans from the Marine-Derived |
AID1657469 | Inhibition of electric eel AChE at 20 uM using acetylthiocholine iodide as substrate incubated for 6 mins by Ellman's method | 2020 | Journal of natural products, 04-24, Volume: 83, Issue:4 | Proximicins F and G and Diproximicin A: Aminofurans from the Marine-Derived |
AID425454 | Cytotoxicity against human HepG2 cells after 48 hrs by sulforhodamine B assay | 2009 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 19, Issue:14 | Synthesis and evaluation of a netropsin-proximicin-hybrid library for DNA binding and cytotoxicity. |
AID1657472 | Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by SRB assay | 2020 | Journal of natural products, 04-24, Volume: 83, Issue:4 | Proximicins F and G and Diproximicin A: Aminofurans from the Marine-Derived |
AID649511 | Induction of apoptosis in human L1236 cells assessed as DNA fragments release from apoptotic nuclei at 50 ug/ml after 48 hrs by propidium iodide based flow cytometry analysis | 2012 | Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6 | Efficient synthesis and biological evaluation of proximicins A, B and C. |
AID1657463 | Antibacterial activity against Staphylococcus aureus ATCC 29213 by CLSI based susceptibility test method | 2020 | Journal of natural products, 04-24, Volume: 83, Issue:4 | Proximicins F and G and Diproximicin A: Aminofurans from the Marine-Derived |
AID649518 | Antimicrobial activity against Enterococcus faecalis NCTC 12697 after 24 hrs by MTT assay | 2012 | Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6 | Efficient synthesis and biological evaluation of proximicins A, B and C. |
AID649516 | Antimicrobial activity against Staphylococcus aureus SA 1199B over-expressing NorA MDR efflux pump after 24 hrs by MTT assay | 2012 | Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6 | Efficient synthesis and biological evaluation of proximicins A, B and C. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (7)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (57.14) | 29.6817 |
2010's | 2 (28.57) | 24.3611 |
2020's | 1 (14.29) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.36
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.36) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |